[Glucagon-like peptide-1 (GLP-1) receptor].
Taminato
Tomohiko
T
Department of Laboratory Medicine, Kagawa Medical University.
D000818:Animals; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy / Q000209:etiology*; D000077270:Exenatide; D005934:Glucagon / Q000502:physiology; D052216:Glucagon-Like Peptide 1; D000067757:Glucagon-Like Peptide-1 Receptor; D004763:Glucagon-Like Peptides; D006801:Humans; D007328:Insulin / Q000378:metabolism; D000078790:Insulin Secretion; D010446:Peptide Fragments / Q000502:physiology; D010455:Peptides / Q000627:therapeutic use; D011110:Polymorphism, Genetic; D011498:Protein Precursors / Q000502:physiology; D018027:Receptors, Glucagon / Q000819:agonists / Q000235:genetics / Q000502:physiology; D014688:Venoms
C000593833:GLP1R protein, human; D000067757:Glucagon-Like Peptide-1 Receptor; D007328:Insulin; D010446:Peptide Fragments; D010455:Peptides; D011498:Protein Precursors; D018027:Receptors, Glucagon; D014688:Venoms; C055453:glucagon-like peptide 1 (7-36)amide; D004763:Glucagon-Like Peptides; D052216:Glucagon-Like Peptide 1; D005934:Glucagon; D000077270:Exenatide